Regen BioPharma (Regen BioPharma) Long-Term Debt : $0.14 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Long-Term Debt?

Regen BioPharma's Long-Term Debt for the quarter that ended in Mar. 2024 was $0.14 Mil.

Regen BioPharma's quarterly Long-Term Debt increased from Sep. 2023 ($0.15 Mil) to Dec. 2023 ($0.15 Mil) but then declined from Dec. 2023 ($0.15 Mil) to Mar. 2024 ($0.14 Mil).

Regen BioPharma's annual Long-Term Debt stayed the same from Sep. 2021 ($0.00 Mil) to Sep. 2022 ($0.00 Mil) but then increased from Sep. 2022 ($0.00 Mil) to Sep. 2023 ($0.15 Mil).

Regen BioPharma Long-Term Debt Historical Data

The historical data trend for Regen BioPharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Long-Term Debt Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Long-Term Debt

Get a 7-Day Free Trial

0.01

0.15

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															-	-	0.15	0.15	0.14

Regen BioPharma (OTCPK:RGBP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Regen BioPharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.